AmbrisentanIt is an orally active, highly selective antagonist of the ET-1 type A receptor, is indicated for the treatment of PAH.
Pulmonary artery hypertension
Oral; 5-10mg once daily.
Hepatic impairement, Hypersensitivity.
Paediatric : safety not established Pregnancy: category X, contraindicated Lactation: Not known wheather excreted in milk. Breastfeeding while receiving ambrisentan is not recommended. Elderly: safe
Vomiting, Right ventricular failure, pulmonary hypertension, acute respiratory failure, cardiac arrest, cardiorespiratory arrest, pneumonia, diarrhea, Hemorrhage, Intracranial, Hepatic enzyme increased, Hypoxia, Pyrexia, Respiratory arrest, sudden death, syncope.
cyclosporine, Digoxin, sildenafil, warfarin, ethinylestradiol, norethindrone.